Durable-polymer versus biodegradable-polymer drug-eluting stents in acute coronary syndromes: three-year outcomes of the HOST REDUCE POLYTECH RCT Trial
EuroIntervention · 2024
DOI: 10.4244/eij-d-23-01053 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift EuroIntervention, 2024. Verfasst von Jeehoon Kang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Seoul National University Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Acute Coronary Syndrome, Polymers, Absorbable Implants. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Long-term follow-up is essential to evaluate the impact of polymer degradation in drug-eluting stents (DES). AIMS: We aimed to compare durable-polymer DES (DP-DES) and biodegradable-polymer DES (BP-DES) during a 3-year follow-up to evaluate the entire period of polymer resolution (before, during, and after degradation). METHODS: The HOST REDUCE POLYTECH RCT Trial was a randomised clinical trial enrolling patients with acute coronary syndrome (ACS) and comparing the efficacy and safety of DP-DES and BP-DES. The primary outcome was a patient-oriented composite outcome (POCO), and the key secondary outcome was a device-oriented composite outcome (DOCO). RESULTS: A total of 3,413 ACS patients were randomised to either the DP-DES (1,713 patients) or BP-DES (1,700 patients) group. During the 3-year follow-up, the risk of the POCO was similar between the DP-DES and BP-DES groups (14.8% vs 15.4%, hazard ratio [HR] 0.96, 95% confidence interval [CI]: 0.80-1.14; p=0.613). However, the risk of the DOCO was lower in the DP-DES group (6.0% vs 8.0%, HR 0.73, 95% CI: 0.57-0.95; p=0.020). In a landmark analysis, the lower risk of the DOCO for the DP-DES group was evident during the transition from the early to the late period after percutaneous coronary intervention (PCI) (from 8 to 16 months post-PCI; 1.8% vs 3.3%, HR 0.54, 95% CI: 0.34-0.84; p=0.007), which was mainly driven by a risk reduction of target lesion revascularisation. CONCLUSIONS: In ACS patients, DP-DES showed similar results to BP-DES regarding the POCO up to 3 years. For the DOCO, DP-DES were superior to BP-DES; this was due to the higher event rate during the period of polymer degradation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Seoul National University Hospital, Seoul, Republic of Korea.
- Hanyang University Seoul Hospital, Seoul, Republic of Korea.
- Presbyterian Medical Center, Jeonju, Republic of Korea.
- Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
- Kangwon National University, Chuncheon, Republic of Korea.
- Seoul Boramae Hospital, Seoul, Republic of Korea.
Zitieren
APA
Kang, J., Hwang, D., Park, K. W., Han, J. K., Yang, H. M., Kang, H. J., Koo, B. K., Lim, Y. H., Rhew, J. Y., Chun, K. J., Lee, B. K., Kim, S., Bae, J. W., Kim, H. S., & Host Reduce Polytech Rct Trial Investigators, O. B. O. T. (2024). Durable-polymer versus biodegradable-polymer drug-eluting stents in acute coronary syndromes: three-year outcomes of the HOST REDUCE POLYTECH RCT Trial. EuroIntervention. https://doi.org/10.4244/eij-d-23-01053
Vancouver
Kang J, Hwang D, Park KW, Han JK, Yang HM, Kang HJ, et al. Durable-polymer versus biodegradable-polymer drug-eluting stents in acute coronary syndromes: three-year outcomes of the HOST REDUCE POLYTECH RCT Trial. EuroIntervention. 2024. doi:10.4244/eij-d-23-01053
BibTeX
@article{Kang2024,
author = {Kang, Jeehoon and Hwang, Doyeon and Park, Kyung Woo and Han, Jung-Kyu and Yang, Han-Mo and Kang, Hyun-Jae and Koo, Bon-Kwon and Lim, Young-Hyo and Rhew, Jay Young and Chun, Kook Jin and Lee, Bong Ki and Kim, Sanghyun and Bae, Jang-Whan and Kim, Hyo-Soo and Host Reduce Polytech Rct Trial Investigators, On Behalf Of The},
title = {Durable-polymer versus biodegradable-polymer drug-eluting stents in acute coronary syndromes: three-year outcomes of the HOST REDUCE POLYTECH RCT Trial},
journal = {EuroIntervention},
year = {2024},
doi = {10.4244/eij-d-23-01053}
}
EUVIMED